

51. Manninen, V., "Tablet Disintegration: Possible Link with Biological Availability of Digoxin," The Lancet, p. 490, Feb. 26, 1972.
52. Cohen, N. A., "The Plasma-Digoxin Controversy," The Lancet, pp. 535-537, March 4, 1972.
53. Levy, R. H., P. M. Lutterbeck and J. Lindenbaum, "Digoxin," The New England Journal of Medicine (letters to the editor), pp. 666-667, March 23, 1972.
54. Butler, V. P., Jr., "Assays of Digitalis in the Blood," Progress in Cardiovascular Diseases, XIV, No. 6:571-600, 1972.
55. Butler, V. P., "Practical Aspects of Immunological Assays," Medical Times, pp. 59-76, May 1972.
56. Livanou, T., E. Voridis, K. Kaplanidis and C. J. Miras, "Digitalis Toxicity," The Lancet, p. 1027, May 6, 1972.
57. Phillips, A. P., "Sources of Error in Radioimmunoassays," The Lancet, pp. 1183-1184, May 27, 1972.
58. Hibble, A. G., P. Isaac and D. G. Grahame-Smith, "Bioavailability of Digoxin," The Lancet, pp. 90-91, July 8, 1972.
59. Smith, T. W., "Contribution of Quantitative Assay Technics to the Understanding of the Clinical Pharmacology of Digitalis," Circulation, XLVI:188-199, 1972.
60. Shapiro, W., K. Taubert and K. Narahara, "Nonradioactive Serum Digoxin and Digitoxin Levels," Archives of Internal Medicine, 130:31-36, 1972.
61. Hamer, J. and D. G. Grahame-Smith, "Bioavailability of Digoxin," The Lancet, p. 325, Aug. 12, 1972.